Obstructive Sleep Apnea as a Cardiovascular Risk Factor-Beyond CPAP

Area of Science:

• Sleep Medicine
• Cardiovascular Research
• Respiratory Medicine

Background:

• Obstructive sleep apnea (OSA) is linked to increased cardiovascular risk due to intermittent hypoxia and sleep disturbances.
• The apnea-hypopnea index (AHI) and hypoxia are key predictors of cardiovascular risk in OSA patients.
• Continuous positive airway pressure (CPAP) is the standard OSA treatment, aiming to reduce AHI and hypoxemia.

Purpose of the Study:

• To review recent clinical trials on CPAP efficacy for cardiovascular event reduction in OSA patients.
• To explore alternative and complementary therapies for OSA beyond CPAP.
• To identify future therapeutic targets for mitigating cardiovascular risk in OSA.

Main Methods:

• Review of three recent randomized clinical trials comparing CPAP to usual care for cardiovascular outcomes.
• Discussion of emerging therapeutic strategies, including neurostimulation.
• Identification of potential future research directions and therapeutic targets.

Main Results:

• Recent large randomized trials failed to demonstrate significant cardiovascular event reduction with CPAP therapy compared to usual care.
• Despite mitigating OSA severity metrics, CPAP did not translate to improved cardiovascular outcomes in these studies.
• The effectiveness of alternative therapies like neurostimulation remains largely untested.

Conclusions:

• Current evidence suggests CPAP alone may not be sufficient to prevent cardiovascular events in all OSA patients.
• Exploring novel therapeutic targets, such as the autonomic nervous system, is crucial for future OSA management.
• Further rigorous research is needed to validate alternative and complementary OSA treatments.